Foghorn Therapeutics presented preclinical data showing complete tumor regression with anti-tumor immune memory using its SMARCA2 inhibitor FHD-909 combined with anti-PD-1 therapy in mouse models.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
From breast cancer to myeloma, Foghorn shows four preclinical programs
4 Preclinical Programs
FHD-909 (SMARCA2 Inhibitor) Lead Compound
Combination With Anti-PD-1 Antibody Treatment Approach
Breast Cancer, Myeloma cancer types targeted